Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
NCT03217253Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in solid tumor, B cell lymphoma and hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events of tazemetostat in patients with varying degrees of hepatic dysfunction up to 2 years and Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction up to 2 years. Planned start Mar 2018; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
solid tumorB cell lymphomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03217253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217253.